NCT05548296 2026-03-24A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaAcrivon TherapeuticsPhase 2 Recruiting353 enrolled
NCT03414047 2022-08-19A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian CancerEli Lilly and CompanyPhase 2 Completed172 enrolled 19 charts